Case Study: MHRA and AstraZeneca
Agile, responsive regulation helps early breast cancer patients to benefit from a study to potentially improve survival outcomes Following MHRA approval of a clinical trial, early breast ca
Disappointment for BMS as Zeposia fails Crohn’s study
Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.
Highlighting the disruptors: Innovation for now and tomorrow...
On Tuesday 19th March, pharmaphorum headed to King’s Place, London for the 10th annual WIRED Health conference - an event partnered with EY, Boston Scientific, and Lingo this year, which se
Akebia joins GSK in US market for oral CKD anaemia drugs
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS
Understanding the politics of drug pricing in the United Sta...
Sometimes the conversation about drug pricing within the pharma industry and the one going on in the wider world seem like they're in completely different languages.
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
PM Society Digital Awards 2024 – Open for Entries
The PM Society Digital Awards 2024 have opened for entries!
Next Gen Peptide Formulation & Delivery Summit
Exciting developments in the world of peptides!
13th HPAPI: Process Development for Highly Potent Drugs
The rise in novel, more potent compounds, alongside EU Annex 1, are mounting pressure on biopharma, CDMOs and equipment providers to evolve their industrial hygiene, process engineering and
3rd In Vivo Cell Engineering & Gene Editing Summit
Achieve Safe & Targeted In Vivo Delivery of Payloads with Clarity in Regulations & Appropriate Models to Advance the Next Frontier of In Vivo Editing from Research to Clinic
Pre-Filled Syringes West Coast Conference
SAE Media Group’s 8th Annual Pre-Filled Syringes West Coast Conference will be back for 2024 in the West Coast to bring together device developers, biotech and big pharma.